Apr 11, 2024, 12:45
Important IMvoke010 trial could shape future research in immunotherapy in locally advanced head and neck cancer – Dana-Farber Cancer Institute
Dana-Farber Cancer Institute shared on X/Twitter:
“Important IMvoke010 trial could shape future research in immunotherapy in locally advanced head and neck cancer after results of 1st phase III study in adjuvant therapy don’t meet event-free survival endpoint. Robert Haddad details findings presented at AACR24. “
Video attached to the link.
Source: Dana-Farber Cancer Institute/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 23, 2024, 03:08
Oct 23, 2024, 02:59
Oct 23, 2024, 02:53
Oct 23, 2024, 02:46
Oct 23, 2024, 00:05
Oct 22, 2024, 23:59
Oct 22, 2024, 23:53